Patents by Inventor Ethan Soudry

Ethan Soudry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hypermethylation biomarkers for detection of head and neck squamous cell cancer
    Patent number: 9328379
    Abstract: Differentially methylated oral squamous cell carcinoma (OSCC) biomarkers, identified in-vitro and validated in well-characterized surgical specimens, have shown poor clinical correlation in cohorts with different risk profiles. To overcome this lack of relevance we used the HumanMethylation27 BeadChip, publicly available methylation and expression array data, and Quantitative Methylation Specific PCR to uncover differential methylation in OSCC clinical samples with heterogeneous risk profiles. A two stage-design consisting of Discovery and Prevalence screens was used to identify differential promoter methylation and deregulated pathways in patients diagnosed with OSCC and head and neck squamous cell carcinoma. This Phase I Biomarker Development Trial identified a panel of differentially methylated genes in normal and OSCC clinical samples from patients with heterogeneous risk profiles. This panel may be useful for early detection and cancer prevention studies.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: May 3, 2016
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Rafael Enrique Guerrero-Preston, David Sidransky, Ethan Soudry
  • Hypermethylation Biomarkers for Detection of Head and Neck Squamous Cell Cancer
    Publication number: 20130071842
    Abstract: Differentially methylated oral squamous cell carcinoma (OSCC) biomarkers, identified in-vitro and validated in well-characterized surgical specimens, have shown poor clinical correlation in cohorts with different risk profiles. To overcome this lack of relevance we used the HumanMethylation27 BeadChip, publicly available methylation and expression array data, and Quantitative Methylation Specific PCR to uncover differential methylation in OSCC clinical samples with heterogeneous risk profiles. A two stage-design consisting of Discovery and Prevalence screens was used to identify differential promoter methylation and deregulated pathways in patients diagnosed with OSCC and head and neck squamous cell carcinoma. This Phase I Biomarker Development Trial identified a panel of differentially methylated genes in normal and OSCC clinical samples from patients with heterogeneous risk profiles. This panel may be useful for early detection and cancer prevention studies.
    Type: Application
    Filed: March 11, 2011
    Publication date: March 21, 2013
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Rafael Enrique Guerrero-Preston, David Sidransky, Ethan Soudry